XtalPi AI Advances Viva-Thera HIV Drug Discovery Program

Boston, Massachusetts, U.S., September 22, 2026

AI Platform Accelerates HIV-1 Candidate Discovery

The collaboration combines Viva-Thera’s expertise in HIV-1 biology and therapeutic target development with XtalPi’s AI-powered drug discovery capabilities. The companies focused on MPER, a highly conserved region of the HIV-1 envelope protein that plays an important role in viral entry and has attracted significant interest as a potential target for broadly acting antiviral therapies. Identifying small molecules capable of effectively interacting with difficult biological targets can require extensive cycles of computational modeling, chemical synthesis, biological testing and optimization. XtalPi’s platform is designed to integrate these activities through AI-driven molecular design and automated research workflows, allowing researchers to evaluate large numbers of potential compounds and prioritize candidates with desirable characteristics.

According to XtalPi, the collaboration achieved preclinical candidate nomination within seven months, demonstrating the potential of an integrated computational and experimental approach to shorten timelines between initial target exploration and selection of a development candidate. The milestone also illustrates how AI technologies are increasingly being incorporated into conventional pharmaceutical discovery processes.

MPER Target Offers New HIV-1 Drug Discovery Opportunity

The HIV-1 MPER region is a particularly attractive target because of its high degree of conservation across viral strains. The region is located on the viral envelope protein and is involved in the membrane-fusion process required for HIV-1 entry into host cells. Therapeutic strategies targeting conserved viral structures could potentially complement existing antiretroviral approaches. Viva-Thera’s program is focused on developing a small-molecule approach against MPER, while XtalPi contributed its computational and experimental drug discovery capabilities. The companies used an integrated workflow covering hit identification, molecular optimization, computational prediction and experimental validation to progress the program toward a preclinical candidate.

The nomination of a PCC does not mean that the candidate has demonstrated clinical efficacy or safety in humans. A preclinical candidate must undergo additional pharmacological, toxicological, formulation and other development studies before it can potentially advance into human clinical trials. Nevertheless, nomination represents an important transition from early discovery toward formal preclinical development. The collaboration therefore demonstrates how AI can potentially contribute to the development of medicines for diseases where new mechanisms and therapeutic strategies remain important. HIV-1 treatment has advanced substantially through combination antiretroviral therapy, but researchers continue to investigate approaches that could address viral persistence, resistance and other long-term challenges.

AI and Automation Reshape Drug Development

XtalPi’s work with Viva-Thera reflects a broader industry movement toward combining artificial intelligence, robotics, computational chemistry and experimental biology to accelerate pharmaceutical discovery. AI systems can help researchers analyze molecular structures, predict properties and prioritize compounds, while automated laboratories can rapidly generate experimental data for iterative optimization. The seven-month timeline reported by XtalPi illustrates the potential value of integrating these capabilities rather than treating computational design and laboratory experimentation as separate stages. Rapid feedback between modeling and experimentation can allow researchers to refine molecular structures and identify promising candidates more efficiently.

For the pharmaceutical industry, such approaches could become increasingly important as researchers tackle complex targets and diseases requiring new therapeutic mechanisms. AI does not eliminate the need for laboratory validation or clinical development, but it can help researchers focus experimental resources on compounds with stronger predicted characteristics. The Viva-Thera collaboration also highlights the potential application of AI-enabled discovery beyond common therapeutic areas. By applying computational and experimental technologies to an HIV-1 MPER-targeting program, the companies are exploring a novel route toward antiviral drug development. As the nominated candidate advances through preclinical development, further studies will be needed to establish its pharmacological profile, safety and potential therapeutic value. The current milestone nevertheless represents a notable example of AI-assisted pharmaceutical innovation, demonstrating how integrated drug discovery platforms can support faster progression from target concept to preclinical candidate.

Source: XtalPi press release